<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856425</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004511-21</org_study_id>
    <secondary_id>2015/2329</secondary_id>
    <nct_id>NCT02856425</nct_id>
  </id_info>
  <brief_title>Trial Of Pembrolizumab And Nintedanib</brief_title>
  <acronym>PEMBIB</acronym>
  <official_title>Phase Ib Trial Of Pembrolizumab And Nintedanib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid&#xD;
      tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the&#xD;
      combination of these two approaches is tolerable. Moreover, comprehensive pre-clinical and&#xD;
      clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy&#xD;
      for the benefit of the patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2016</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of Nintedanib</measure>
    <time_frame>Assessed within 24 months after study start</time_frame>
    <description>The primary endpoint is to determine the MTD of nintedanib based on the assessment of DLT occurrence during treatment Course 1.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Patients With Any Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>NSCLC of adenocarcinoma tumor hist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC of squamous cell tumor histo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Urothelial cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal Cell cancer (RCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Colo Rectal Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian cancer (OC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatocellular (HCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesothelioma (MPM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details</description>
    <arm_group_label>Colo Rectal Cancer</arm_group_label>
    <arm_group_label>Hepatocellular (HCC)</arm_group_label>
    <arm_group_label>Mesothelioma (MPM)</arm_group_label>
    <arm_group_label>NSCLC of adenocarcinoma tumor hist</arm_group_label>
    <arm_group_label>NSCLC of squamous cell tumor histo</arm_group_label>
    <arm_group_label>Ovarian cancer (OC)</arm_group_label>
    <arm_group_label>Renal Cell cancer (RCC)</arm_group_label>
    <arm_group_label>Urothelial cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details</description>
    <arm_group_label>Colo Rectal Cancer</arm_group_label>
    <arm_group_label>Hepatocellular (HCC)</arm_group_label>
    <arm_group_label>Mesothelioma (MPM)</arm_group_label>
    <arm_group_label>NSCLC of adenocarcinoma tumor hist</arm_group_label>
    <arm_group_label>NSCLC of squamous cell tumor histo</arm_group_label>
    <arm_group_label>Ovarian cancer (OC)</arm_group_label>
    <arm_group_label>Renal Cell cancer (RCC)</arm_group_label>
    <arm_group_label>Urothelial cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18&#xD;
&#xD;
          2. Cytologically or histologically confirmed diagnosis of advanced solid tumor for the&#xD;
             initial cohort (all tumor types).&#xD;
&#xD;
             And for the Expansion cohorts:&#xD;
&#xD;
             2.1. Patients with locally advanced, metastatic or locally recurrent non-small cell&#xD;
             lung cancer (NSCLC) of adenocarcinoma tumor histology in the first line of systemic&#xD;
             therapy. Relapsing stage III previously irradiated are allowed if the irradiation has&#xD;
             been performed more than 6 months before C1D1.&#xD;
&#xD;
             2.2 Patients with locally advanced, metastatic or locally recurrent non-small cell&#xD;
             lung cancer (NSCLC) of squamous cell tumor histology in the first line of systemic&#xD;
             therapy. Relapsing stage III previously irradiated are allowed if the irradiation has&#xD;
             been performed more than 6 months before C1D1.&#xD;
&#xD;
             2.3. Patients with advanced Urothelial cancer&#xD;
&#xD;
             2.4. Patients with advanced Renal Cell cancer (RCC)&#xD;
&#xD;
             2.5. Patients with advanced Mesothelioma (MPM)&#xD;
&#xD;
             2.6. Patients with advanced squamous cell carcinoma in cervical cancer&#xD;
&#xD;
             2.7. Patients with advanced Hepatocellular (HCC)&#xD;
&#xD;
             2.8. Patients with advanced thymic carcinoma&#xD;
&#xD;
          3. ECOG performance status of score 0 or 1&#xD;
&#xD;
          4. Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  Proteinuria ≤ Grade 2 NCI CTCAE v4.03&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
               -  Total bilirubin within normal range ≤1.5 x ULN (≤ 3 if HCC)&#xD;
&#xD;
               -  AST and ALT ≤1.5 x upper limit of normal (ULN); if liver metastases AST and ALT&#xD;
                  ≤2.5 x ULN if HCC&#xD;
&#xD;
               -  Coagulation parameter : International normalized ratio (INR) &lt; 2, prothrombin&#xD;
                  time (PT) and partial thromboplastin time (PTT) &lt; 50% of deviation of ULN&#xD;
&#xD;
               -  Absolute Neutrophils count (ANC) ≥1 000 cells/mm3&#xD;
&#xD;
               -  Platelets ≥100 000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          5. Failure of at least one prior line of chemotherapy (except for the NSCLC cohorts)&#xD;
&#xD;
          6. At least one measurable lesion according to RECIST v1.1 criteria and modified RECIST&#xD;
             for mesothelioma only or any other baseline prerequisite for the assessment of the&#xD;
             principal judgment criteria.&#xD;
&#xD;
          7. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test within 7 days prior to initiation of treatment. Both sexually active females and&#xD;
             males (and their female partners) patients must agree to use two methods of effective&#xD;
             contraception, one of them being a barrier method, or to abstain from sexual activity&#xD;
             during the study and for at least 4 months after last study drug administration.&#xD;
&#xD;
          8. Signed and dated written informed consent prior to admission to the study&#xD;
&#xD;
          9. Patient affiliated to a social security regimen or beneficiary or the same&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with nintedanib&#xD;
&#xD;
          2. Known hypersensitivity to trial drugs or their excipients, peanut or soya or to&#xD;
             contrast media&#xD;
&#xD;
          3. Prior treatment with pembrolizumab or any other anti PD1 or anti-PDL1 agents&#xD;
&#xD;
          4. Concurrent steroid medication (except topical or aerosol steroids). Any steroid&#xD;
             medication should have been stopped for more than 7 days prior beginning of therapy.&#xD;
&#xD;
          5. History of autoimmune/immune mediated inflammatory disease, including but not limited&#xD;
             to colitis, pneumonitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, systemic&#xD;
             lupus erythematous, rheumatoid arthritis, inflammatory bowel disease, Wegener's&#xD;
             granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, vasculitis, or&#xD;
             glomerulonephritis. Patients with a history of auto-immune endocrinopathy (hypo/hyper&#xD;
             thyroiditis,type 1 diabetes mellitus, …) and who are stable on hormone replacement&#xD;
             therapy are eligible for the study. Patients with a history of vitiligo, pelade,&#xD;
             cutaneous psoriasis and grade 1-2 Sjogren syndrome are eligible.&#xD;
&#xD;
          6. Chemo-, hormono-, radio- (except for brain and extremities) or immunotherapy or&#xD;
             therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past&#xD;
             4 weeks or 5 half-life times (whatever the shortest) prior to treatment with the trial&#xD;
             drugs.&#xD;
&#xD;
          7. Administration of a live, attenuated vaccine within 4 weeks before registration&#xD;
&#xD;
          8. Treatment with systemic immunosuppressive medications (including but not limited to&#xD;
             steroids azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor&#xD;
             [anti-TNF] agents) within 2 weeks prior to registration&#xD;
&#xD;
          9. Radiotherapy to the target lesion (unless a progression after radiotherapy has been&#xD;
             documented)&#xD;
&#xD;
         10. Persistence of clinically relevant treatment-related toxicity from previous&#xD;
             chemotherapy, targeted therapy and/or radiotherapy&#xD;
&#xD;
         11. Active brain metastases or leptomeningeal disease. Clinically asymptomatic brain&#xD;
             metastases and clinically asymptomatic leptomeningeal disease are allowed (treatment&#xD;
             with steroids prior initiation of the trial is not allowed). Patients with Diffuse&#xD;
             Intrinsic Pontine Gliomas, even asymptomatic, are not allowed.&#xD;
&#xD;
         12. Radiographic evidence of cavitary or necrotic tumors or tumors with local invasion of&#xD;
             major blood vessels&#xD;
&#xD;
         13. History of clinically significant hemoptysis within the past 3 months (more than one&#xD;
             teaspoon of fresh blood per day)&#xD;
&#xD;
         14. Treatment with other investigational drugs or treatment in another clinical trial&#xD;
             within the past 4 weeks before start of therapy or concomitantly with the trial&#xD;
&#xD;
         15. Therapeutic anticoagulation with drugs requiring INR monitoring (except low-dose&#xD;
             heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous&#xD;
             devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic&#xD;
             acid &lt; 325mg per day)&#xD;
&#xD;
         16. Major injuries and/or surgery within the past 4 weeks prior to start of study&#xD;
             treatment with incomplete wound healing and/or planned surgery during the on-treatment&#xD;
             study period&#xD;
&#xD;
         17. History of clinically significant hemorrhagic or thromboembolic event in the past 6&#xD;
             months&#xD;
&#xD;
         18. Known inherited (genetic) predisposition to bleeding or thrombosis (such deficit in&#xD;
             protein C/S) or acquired predisposition to thrombosis (such as anti-phospholipid&#xD;
             syndromes)&#xD;
&#xD;
         19. History of significant cardiovascular diseases ( i.e. uncontrolled hypertension,&#xD;
             unstable angina, history of infarction within the past 12 months prior to start of&#xD;
             study treatment, congestive heart failure &gt; NYHA II, serious cardiac arrhythmia,&#xD;
             pericardial effusion)&#xD;
&#xD;
         20. Ongoing uncontrolled auto-immune thyroiditis. Ancient thyroiditis currently stable&#xD;
             with substitutive therapy should not be excluded from the trial.&#xD;
&#xD;
         21. Other malignancies within the past 5 years other than basal cell skin cancer or&#xD;
             carcinoma in situ of the cervix. A history of more than 3 years of local prostate&#xD;
             cancer treated by surgery and without PSA elevation since surgery, or local breast&#xD;
             carcinoma treated by surgery without relapse are eligible.&#xD;
&#xD;
         22. Active serious infections in particular if requiring systemic antibiotic or&#xD;
             antimicrobial therapy&#xD;
&#xD;
        24. Known to be human immunodeficiency virus (HIV) positive; 25. Gastrointestinal disorders&#xD;
        or abnormalities that would interfere with absorption of the study drug 26. Serious illness&#xD;
        or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease&#xD;
        or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may&#xD;
        increase the risk associated with study participation or study drug administration and in&#xD;
        the judgment of the investigator would make the patient inappropriate for entry into the&#xD;
        study.&#xD;
&#xD;
        27. Pregnancy or breast feeding, 28. Psychological, familial, sociological or geographical&#xD;
        factors potentially hampering compliance with the study protocol and follow-up schedule 29.&#xD;
        Active alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aurélien Marabelle, MD</last_name>
    <phone>0142114296</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelien.marabelle@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier Paoletti, MD</last_name>
    <phone>0142116564</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.paoletti@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien Marabelle, MD</last_name>
      <phone>0142114296</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelien.marabelle@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Xavier Paoletti, MD</last_name>
      <phone>0142116564</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.paoletti@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

